Journal ArticleDOI
Deferoxamine (desferrioxamine). New toxicities for an old drug.
Reads0
Chats0
TLDR
Iron is an esssential element for body homoeostasis, but there is no effective mechanism for elimination of an excess of this mineral, so deferoxamine (desferrioxamine) is currently the treatment of choice for iron overload states from both acute iron intoxication and transfusion-dependent anaemias.Abstract:
Iron is an essential element for body homoeostasis, but there is no effective mechanism for elimination of an excess of this mineral. Deferoxamine (desferrioxamine) is currently the treatment of choice for iron overload states from both acute iron intoxication and transfusion-dependent anaemias. The pharmacokinetics of deferoxamine are confounded both by its ability to chelate endogenous and exogenous iron and by the laboratory techniques used for its determination. Its iron-complex (ferrioxamine) has different pharmacokinetic properties. Because of its effectiveness, the use of deferoxamine is becoming more common, involving long term and high dose regimens. As a result of this, more and more toxicities that were not known in the past have been described and characterised. The most serious of these include hypotension, renal insufficiency, neurotoxicity, growth retardation and opportunistic infections: some of these side effects may be attributed to or aggravated by ferrioxamine. The pharmacological and toxicological literature on deferoxamine, and possible mechanisms for its toxicity, are reviewed and discussed.read more
Citations
More filters
Journal ArticleDOI
5‐Aminolevulinic Acid‐Based Photodynamic Therapy: Principles and Experimental Research
TL;DR: Because PpIX is an efficient photosensitizer, ALA has been introduced as a drug for clinical photodynamic therapy (PDT) of cancer (8,9).
Journal ArticleDOI
The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats.
TL;DR: It is suggested that DFO protects against acute DXR-induced cardiotoxicity in a dose-dependent manner with recognizing the presence of mild DFO-related biochemical and cytological hepatic toxicity.
Journal ArticleDOI
Bifunctional antimicrobial conjugates and hybrid antimicrobials
Philipp Klahn,Mark Brönstrup +1 more
TL;DR: 'Trojan Horse' approaches can expand the antibacterial activity of compounds against Gram-negative pathogens, or offer new options for natural products that could not be developed as standalone antibiotics, e.g. due to their toxicity.
Book
Drug-Induced Ocular Side Effects
TL;DR: Anti-Infectives Agents Affecting the Central Nervous System Analgesics, Narcotic Antagonists and Agents Used to Treat Arthritis Agents used in Anesthesia Gastrointestinal Agents Cardiac, Vascular, and Renal Agents Hormones and Agents Affected Hormonal Mechanisms Agents Affects Blood Formation and Coagulability
Journal ArticleDOI
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Yun Yen,Kim Margolin,James H. Doroshow,Mayer Fishman,Bonny Johnson,Caroline Clairmont,Daniel M. Sullivan,Mario Sznol +7 more
TL;DR: 3-AP and gemcitabine combination demonstrated antitumor activity and merits further exploration in phase II trials, and 3-AP was shown to cause mild, reversible methemoglobinemia.
References
More filters
Journal ArticleDOI
The biochemistry of desferrioxamine and its relation to iron metabolism.
TL;DR: The stability constants for various desferrioxamine-metal complexes compared with the constants for other chelating agents are listed in TABLE l.596 The higher the constant, the more stable the complex.
Journal ArticleDOI
Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
Nancy F. Olivieri,Buncic,Emily Y. Chew,Tsvi Gallant,Robert V. Harrison,Nancy K. Keenan,William J. Logan,David J. Mitchell,Ricci G,Barry Skarf +9 more
TL;DR: Of 89 patients receiving nightly subcutaneous deferoxamine for transfusion-dependent thalassemia major or Diamond-Blackfan anemia, 13 presented with visual loss or deafness of acute onset or both, and detailed ophthalmologic, audiologic, and evoked-potential studies uncovered abnormalities caused by neurotoxicity in 27 more.
Journal ArticleDOI
Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation
TL;DR: The binding of iron by deferoxamine likely causes an inhibition of ribonucleotide reductase activity, thereby preventing cells from completing the S phase of the cell proliferation cycle, and may have important experimental and therapeutic applications.
Journal ArticleDOI
Ocular toxicity of high-dose intravenous desferrioxamine
TL;DR: Desferrioxamine was given intravenously, at higher doses than previously reported, to counter the effects of transfusion-induced iron overload in four patients with beta thalassaemia major, and retinal abnormalities developed, presenting with night blindness and field defects.
Journal ArticleDOI
Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells.
TL;DR: Phytohaemagglutinin‐stimulated lymphocytes from patients with chronic iron deficiency showed lower levels of all four deoxyribonucleoside triphosphates than normal lymphocytes, suggested that this may be due to reduced ribonucleotide reductase activity of the iron‐deficient cells.